The new data comes from the 1,162-subject LUCENT-1 trial – first unveiled last year – which compared induction treatment with the anti-IL-23p19 antibody to placebo in patients with moderately-to-severely active ulcerative colitis who had not tried a biologic therapy before.
The study found that 24% of patients treated with mirikizumab were in clinical remission at 12 weeks – meaning inflammation of the colon is controlled or resolved – compared to 13% of the placebo group.